Eledon pharmaceuticals appoints industry veteran james robinson to its board of directors

Irvine, calif., sept. 11, 2023 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced the appointment of james robinson to its board of directors effective october 1, 2023. mr. robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as chief executive officer and director of urovant sciences until its merger with sumitomo pharma america on july 1, 2023.
ELDN Ratings Summary
ELDN Quant Ranking